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Abstract
Background: COPD patients have a higher risk of pneumonia when treated with fluticasone propionate (FP) than
with placebo, and a lower risk with budesonide (BUD). We hypothesized that BUD and FP differentially affect the
mucosal barrier in response to viral infection and/or cigarette smoke.
Methods: We assessed protective effects of equivalent concentrations of BUD and FP on cytokine production and
barrier function (electrical resistance) in human bronchial epithelial 16HBE cells and primary bronchial epithelial
cells (PBECs) upon exposure to viral mimetic poly-(I:C) and/or cigarette smoke extract (CSE) or epidermal growth
factor (EGF).
Results: BUD and FP were equally effective in suppressing poly-(I:C)- and/or CSE-induced IL-8 secretion in 16HBE and
PBECs. Poly-(I:C) substantially decreased electrical resistance in 16HBE cells and both BUD and FP fully counteracted this
effect. However, FP hardly affected 16HBE barrier dysfunction induced by CSE with/without poly-(I:C), whereas
BUD (16 nM) provided full protection, an effect likely mediated by affecting EGFR-downstream target GSK-3β.
Similarly, BUD, but not FP, significantly improved CSE-induced barrier dysfunction in PBECs. Finally, BUD, but not FP,
exerted a modest but significant protective effect against Streptococcus Pneumoniae-induced barrier dysfunction, and
BUD, but not FP, prevented cellular adhesion and/or internalization of these bacteria induced by poly-(I:C) in 16HBE.
Conclusions: Collectively, both BUD and FP efficiently control epithelial pro-inflammatory responses and barrier
function upon mimicry of viral infection. Of potential clinical relevance, BUD more effectively counteracted
CSE-induced barrier dysfunction, reinforcing the epithelial barrier and potentially limiting access of pathogens
upon smoking in vivo.
Keywords: Bronchial epithelial cells, COPD, Pneumonia, Cigarette smoke extract, Poly-(I:C)
Background
Chronic Obstructive Pulmonary Disease (COPD) is a
chronic inflammatory respiratory disease affecting mil-
lions of people worldwide. Inhaled corticosteroids (ICS)
are widely used in the management of COPD. ICS ef-
fectively reduce the number of exacerbations and im-
prove respiratory symptoms and quality of life [1].
However, ICS use may also increase the risk of pneumo-
nia in COPD [2, 3]. The TORCH study demonstrated
this for the first time, comparing fluticasone propionate
(FP) and placebo [2, 3]. Findings from this study were
confirmed in a meta-analysis by Singh and colleagues
[4]. Sixteen of the 18 studies included in the meta-
analysis of Singh and colleagues investigated the effects
of FP or FP/salmeterol, and it remained unclear whether
the increased pneumonia risk would be FP specific or a
class effect of ICS and also present with budesonide
(BUD) treatment. More recent studies suggested that
pneumonia events were lower with BUD than with FP
treatment [5, 6]. Furthemore, Suissa and colleagues
* Correspondence: h.i.heijink@umcg.nl
1Department of Pathology & Medical Biology, Experimental Pulmonology
and Inflammation Research, University of Groningen, University Medical
Center Groningen,, Hanzeplein 1, NL-9713 GZ, Groningen, The Netherlands
2Department of Pulmonology, University of Groningen, University Medical
Center Groningen, Groningen, The Netherlands
Full list of author information is available at the end of the article
© 2016 Heijink et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Heijink et al. Respiratory Research  (2016) 17:2 
DOI 10.1186/s12931-015-0318-z
reported that FP treatment is associated with a substan-
tial increase in the risk of serious pneumonia in COPD
patients, while the risk with BUD was comparatively
low, even at high doses [7]. Most recently, Suissa and
colleagues reported that discontinuation of ICS use in
COPD is associated with a reduction in the elevated risk
of serious pneumonia, especially for FP [8]. Thus, the in-
creased risk to develop pneumonia in COPD may be
specific to the use of FP and not the result of a class ef-
fect of ICS. The cellular mechanisms underlying these
differences in safety for ICS use in COPD patients are
not well understood. BUD is less lipophilic than FP and
has a higher aqueous solubility, leading to a shorter re-
tention time in the lining fluid of the airways, while after
being absorbed, BUD is retained in airway tissue/epithe-
lium for a longer time than FP [9, 10]. It is as yet un-
known how this may affect the action of BUD and FP in
epithelial cells.
The bronchial epithelium forms the first continuous
physical barrier to microbial infections and is part of the
innate immune response, producing antimicrobial and
pro-inflammatory peptides/cytokines acting on immune
cells, the latter especially when the epithelial layer is
damaged. In COPD, aberrant epithelial repair in re-
sponse to cigarette smoking may disturb epithelial bar-
rier function [11] and we previously observed a
reduction in epithelial barrier function upon smoke ex-
tract exposure in vitro [12]. Compromised barrier func-
tion may render the airways more susceptible to
pathogens, and accordingly, rhinovirus-induced barrier
dysfunction in mice was shown to increase the risk of a
secondary bacterial infection [13]. The corticosteroid
dexamethasone improves airway and corneal epithelial
barrier function in vitro [14–16].
We hypothesized that BUD is more effective than
FP in protecting against airway epithelial barrier dys-
function upon damage by environmental insults. Viral
infection may predispose to bacterial pneumonia, acti-
vating toll-like receptor 3 (TLR3) on airway epithe-
lium [13, 17]. TLR3-dependent effects have also been
demonstrated for Haemophilus Influenza, one of the
most common causes of pneumonia in COPD [18].
Therefore, we compared the effect of BUD and FP on
viral mimetic poly-(I:C) and/or cigarette smoke-
induced epithelial barrier function and pro-
inflammatory cytokine production in both the human
bronchial epithelial cell line 16HBE and cultured pri-
mary bronchial epithelial cells (PBECs) of smoking in-
dividuals with normal lung function.
Methods
Cell culture
The human bronchial epithelial cell line 16HBE was
kindly provided by Dr. D.C. Gruenert (University of
California, San Francisco, CA) and cultured in EMEM
medium/10 % FCS (Biowhittaker, Verviers, Belgium)
supplemented with 100 U/ml penicillin and 100 μg/ml
streptomycin on collagen-coated flasks as described pre-
viously [19]. PBEC cultures were obtained from bronchial
brushings in six current smoking individuals with ≥10
pack-years, FEV1/FVC > 70 % and FEV1 > 90 % of pre-
dicted and not using inhaled corticosteroids, long-acting
β2- adrenergic agonists and long-acting anticholinergics
for at least 4 weeks preceding the study. The Medical Eth-
ics Committee of the University Hospital of Groningen
approved the study. All subjects gave their written in-
formed consent. For studies in mucociliary differentiated
cells, PBECs were obtained by protease digestion from
trachea-bronchial tissue of 10 non-COPD donor lungs.
The study protocol was consistent with the Research Code
of the University Medical Center Groningen (http://
www.rug.nl/umcg/ onderzoek/researchcode/index) and
national ethical and professional guidelines (“Code of con-
duct; Dutch federation of biomedical scientific societies”;
htttp://www.federa.org). Cells were cultured as described
previously [20] in bronchial epithelium growth medium
(BEGM, Lonza, Walkersville, MD) on collagen/fibronec-
tin-coated flasks and stored in liquid nitrogen to be used
for experiments at later time in passage 3.
Treatment of the cells
We used BUD and FP in equivalent concentrations with
a dose ratio of FP:BUD = 1.6, based on the observations
from clinical studies that 800 μg BUD is equivalent to
500 μg FP. Cells were pre-treated with or without BUD
or FP for 2 hours and subsequently exposed to vehicle
(medium), 5 or 7.5 % CSE [12], poly-I:C (12.5 μg/ml),
EGF (10 ng/ml) or GSK-3β inhibitor CT99021 (1 μM)
for 1–24 hours.
Viral infection in air-liquid interface-cultured epithelial cells
To induce mucociliary differentiation at the air-liquid
interface (ALI), the PBECs from non-COPD donors were
grown in duplicates on semi-permeable membranes
coated with 30 μg/ml collagen 10 μg/ml fibronectin and
10 μg/ml BSA in a 1:1 mixture of DMEM (Lonza) and
BEGM supplemented with retinoic acid (RA, 15 ng/ml;
Sigma, St. Louis, MO, USA) and exposed to air for
4 weeks as described previously [20]. Cells were hormo-
nally deprived overnight. For infection with live rhino-
virus (RV; major receptor group RV-16, kind gift of D.
Davies, University of Southampton, UK), cells in an
identically seeded well were counted to calculate multi-
plicity of infection (MOI) and the virus concentration
was adjusted to the number of cells. The apical surface
was infected with 50 μl RV16 with an MOI of 1 for
24 hours at 37 °C before harvesting for RNA isolation
and collection of supernatants.
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Exposure to Streptococcus pneumoniae
For bacterial infection, Streptococcus pneumoniae strain
TIGR4Δcps was used. S. pneumoniae was grown in M17
broth (Oxoid,Hamshire, UK) supplemented with 0.5 %
glucose, or on blood agar plates (Mediaproducts bv,
Groningen, The Netherlands) as described previously
[21]. For start inoculations in all experiments, S. pneu-
moniae aliquots were made by growing S. pneumoniae
in M17 supplemented with glucose to a 600 nm optical
density of ~0.25, mixed to a 10 % glycerol concentration
and then frozen in 1 ml aliquots at −80 °C. Prior to in-
fection, confluent 16HBE cell monolayers in uncoated
transwell plates (Transwell, 3 μm pore-size, 6.5 mm
diameter; Costar #3472, Costar Corning Inc., Cambridge,
MA) were incubated for 2 hour in infection assay
medium, with and without 16 nM BUD and 10 nM FP.
Subsequently, ~5*106 CFU of S. pneumoniae were added
per well and incubated for 2–24 hours, in the presence
and absence of 12.5 μg poly-(I:C). To assess S. pneumo-
niae adhesion/internalization, 16HBE cells were washed
with PBS/0.01 % CaCl2 and subsequently lysed with
PBS/0.1 % Triton. Colony forming units (CFUs) were de-
termined by plating serial dilutions on blood agar plates.
For analysis of transmigration, the medium was removed
from the basolateral compartment after 2, 4 or 24 hours
and plated for CFU determination. Before and 24 hours
after bacterial infection, transepithelial resistance was
measured using a volt-ohmmeter (EVOM, world preci-
sion instruments, Sarasota, FL).
Preparation of cigarette smoke extract
Cigarette smoke extract (CSE) was prepared as described
previously [22]. In short, Kentucky 3R4F research-
reference cigarettes (The Tobacco Research Institute,
Lexington, KY) were used without filter. Smoke from
two cigarettes was bubbled through 25 ml medium
(100 % CSE). The extract was prepared freshly.
Electric Cell-surface Impedance Sensing (ECIS)
Electrical resistance of submerged cultured cells was mea-
sured using ECIS (Applied Biophysics, Troy, NY) as de-
scribed previously [23, 24]. Resistance and capacitance
were measured at 400 Hz and 40 kHz, respectively. In the
ECIS system, all established resistance values were be-
tween 10,000-20,000Ω in the 16HBE cultures and ~1,500
Ω in the primary cell cultures.
Western blotting
Total cell lysates were obtained and subjected to western
blotting using antibodies against E-cadherin, phospho-
EGF receptor (EGFR), actin, GAPDH (Santa Cruz Bio-
technology, Santa Cruz, CA), zona occludens (ZO)-1
(Invitrogen, Carlsbad, CA, USA) and phospho-GSK-3β
(Cell Signalling Technology, Herts, UK) as described
previously [25]. Protein levels were quantified using the
gelscan program QuantityOne.
Immunofluorescent staining of ZO-1
Cells grown on LabTeks were washed with PBS/CaCl2,
fixed in ice-cold acetone (90 %) for 30 min, blocked in
PBS/5 % BSA for 60 min, incubated for 60 min with
primary antibodies (1:200) against ZO-1 (Invitrogen)
and subsequently incubated for 60 min with FITC-
labeled anti-rabbit (1:200, DAKO, Glostrup, Denmark)
or Rhodamine-labeled anti-mouse IgG conjugates
(1:400, Jackson Immunoresearch Laboratories, West
Grove, PA).
Measurement of gene expression with qPCR
RNA was isolated from 16HBE and cDNA synthesized
as described previously [26]. We analyzed the expression
of E-cadherin and the housekeeping genes PPIA and
β2μG. Analyses were performed by real-time PCR using
Taqman according to manufacturer’s guidelines using
validated probes and the TaqMan Master (Applied Bio-
systems, Foster City, CA).
Measurement of IL-8 levels
Protein levels were measured in cell-free supernatants
using ELISA kits according to manufacturer’s guidelines
(R&D systems Europe Ltd., Abingdon, UK).
Statistics
Data were analyzed using the paired Student’s t-test, the
Wilcoxon-signed rank test or repeated measures
ANOVA for ECIS experiments as indicated. Differences
were considered statistically significant at p < 0.05.
Results
Effects of BUD and FP on cytokine release in 16HBE cells
and PBECs
We first assessed the effects of BUD and FP on pro-
inflammatory epithelial responses. Exposure to poly-
(I:C) for 24 hours strongly increased the secretion of
neutrophil chemo-attractant IL-8 (CXCL8), which was
completely suppressed by both BUD (0.16, 1.6 and 16
nM) and FP (0.1, 1 and 10 nM, Fig. 1A). Baseline and
CSE (5 % for 24 hours)-induced IL-8 levels were also
equally efficiently suppressed by BUD (16 nM) and FP
(10 nM, Fig. 1B). Furthermore, the combination of CSE
(5 %) and poly-(I:C) strongly enhanced IL-8 secretion,
which was completely and equally efficiently suppressed
by BUD (16 nM) and FP (10 nM, Fig. 1C). Thus, both
BUD and FP effectively suppress the production of the
pro-inflammatory cytokine IL-8 upon stimulation with
CSE and/or poly-(I:C).
To increase the translational relevance, we also studied
primary bronchial epithelial cells (PBECs) from smoking
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Fig. 1 (See legend on next page.)
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individuals using poly-(I:C), the most potent inducer of
IL-8 secretion in 16HBE cells. Poly-(I:C) also strongly in-
creased IL-8 secretion in PBECs, which was equally and
significantly suppressed by BUD and FP (Fig. 1D,E).
Effects of BUD and FP on cigarette smoke-induced barrier
dysfunction of 16HBE cells and PBECs
In addition to pro-inflammatory responses, we studied
epithelial barrier function using ECIS. The electrical re-
sistance measured by ECIS at a low frequency (i.e.
400 Hz) is highly sensitive to changes in specifically epi-
thelial cell-cell contacts [23, 24]. CSE (7.5 %) induced a
marked decrease in electrical resistance (barrier func-
tion) of 16HBE cells from 12 hours exposure onwards,
with a maximal effect around 24 hours (Fig. 2A). There-
after, barrier function started to recover slowly (data not
shown). CSE did not clearly affect the high-frequency
capacitance, a more sensitive parameter to monitor
changes in cell-matrix contact (Fig. 2B), indicating that
CSE affects epithelial cell-cell contacts rather than cell
attachment or viability, in line with our previous obser-
vations [12]. When comparing the effects of the equiva-
lent concentrations of 2-hours pre-treatment with 16
nM BUD and 10 nM FP on CSE-induced barrier func-
tion in 16HBE cells, FP only modestly, but not signifi-
cantly attenuated CSE-induced barrier dysfunction,
while BUD almost completely prevented the CSE-
induced defect in barrier function within 24 hours, the
difference between the effect of BUD and FP being sta-
tistically significant (Fig. 2A). Similarly to the effects in
16HBE cells, CSE (5 %) markedly reduced electrical re-
sistance in a PBEC monolayer (Fig. 2C). BUD (16 nM)
slightly but significantly counteracted the CSE-induced
barrier dysfunction, while no significant effect of FP (10
nM) was observed (Fig. 2D). Since the effect of BUD
was not as strong as in 16HBE cells, we tested the effect
of higher concentrations of BUD and FP (160 nM and
100 nM, respectively). However, neither BUD nor FP
exerted a significant effect on CSE-induced barrier dys-
function at this concentration (data not shown). Never-
theless, these results confirm the findings in 16HBE
cells, indicating that also in primary epithelial cells BUD
and FP differentially affect cigarette-smoke induced bar-
rier dysfunction, while they are equally effective in the
inhibition of pro-inflammatory responses.
Effects of BUD and FP on EGF-induced barrier dysfunction
and EGFR downstream signaling
To elucidate the mechanism involved in the differential
effect of BUD and FP on CSE-induced barrier dysfunc-
tion, we first assessed whether the observed effects are
exerted on epithelial cell-cell contacts. We studied the
expression of the adherens junction protein E-cadherin
and the tight junction protein ZO-1 in the presence of
CSE. CSE (7.5 % for 24 hours) exposure did not signifi-
cantly affect total protein expression of ZO-1 and E-
cadherin, nor did the addition of BUD or FP (Fig. 3A).
Accordingly, mRNA expression of E-cadherin did not
change upon CSE (7.5 % for 6 hours) exposure alone or
in the presence of BUD and FP (Fig. 3B). On the other
hand and in line with our previous observations [12],
CSE (7.5 % for 24 hours) disrupted junctional ZO-1 ex-
pression as assessed by immunofluorescent staining
(Fig. 3C). The presence of either BUD or FP attenuated
this effect, while differences between BUD and FP treat-
ment were hardly visible using this semi-quantitative
technique. We previously observed that EGFR activation
is involved in CSE-induced barrier dysfunction and dis-
ruption of ZO-1 expression [12]. Therefore, we also
studied the effect of BUD and FP upon exposure to
EGF. We observed that BUD, but not FP, significantly
counteracted the EGF-induced epithelial barrier dysfunc-
tion (Fig. 4A), with also a significant difference between
the effect of BUD and FP. Western blotting revealed that
EGF-induced EGFR Tyr1174 phosphorylation between
30–120 min (data not shown), with the most pro-
nounced effect at 60 min (Fig. 4B). BUD significantly re-
duced EGF-induced EGFR phosphorylation, leaving total
EGFR levels unaffected, while FP had no effect on
phospho-EGFR levels (Fig. 4B). These data suggest that
only BUD attenuates EGFR activation and subsequent
disruption of cell-cell contacts.
(See figure on previous page.)
Fig. 1 Effect of equivalent concentrations of budesonide (BUD) and fluticasone propionate (FP) on cigarette smoke extract (CSE) and/or
poly-(I:C)-induced IL-8 (CXCL8) release in 16HBE cells and primary bronchial epithelial cells (PBECs). 16HBE cells and PBECs were seeded in
duplicates, grown to confluence for 3–4 days, serum-deprived (16HBE) or placed on basal medium with transferrin and insulin (PBECs)
overnight, pre-treated with or without 0.16-16 nM BUD or 0.1−10 nM FP for 2 hours and stimulated with 5 % CSE and/or 12.5 μg poly-(I:C) for 24 hours.
IL-8 was measured in cell-free supernatants. a Mean ± SEM IL-8 levels (pg/ml) in 16HBE cells at baseline and upon stimulation with poly-(I:C) in
the presence and absence of different concentrations of BUD and FP (n = 4). b Mean ± SEM IL-8 levels (pg/ml) in 16HBE cells at baseline and
upon stimulation cells with 5 % CSE in the presence and absence of 16 nM BUD and 10 nM FP (n = 4). c Mean ± SEM IL-8 levels (pg/
ml) in 16HBE cells upon combined stimulation with CSE + poly-(I:C) in the presence and absence of 16 nM BUD and 10 nM FP (n = 4).
PBECs were exposed to 12.5 μg/ml poly-(I:C) for 24 hours and absolute IL-8 levels (pg/ml, min to max) (d) or values normalized to the
absence of BUD or FP (percentage, mean ± SEM) (e) are shown (n = 6). * = p < 0.05 and ** = p < 0.01 between the indicated values or
between the absence and presence of BUD or FP as determined by the Student’s t-test (assumed normal distribution) (a-c, e) or the
Wilcoxon-signed rank test (d)
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Dexamethasone can attenuate the inhibitory phosphor-
ylation of EGFR downstream target GSK-3β [27, 28] .
Therefore we assessed whether BUD and FP differently
affect the EGF-induced inhibitory phosphorylation of
GSK-3β at Ser9. Indeed, EGF significantly increased GSK-
3β phosphorylation between 30–120 min (data not
shown), with the most pronounced effect at 60 min, which
was significantly reduced by BUD, but not FP, while total
GSK-3β levels were not affected by BUD or FP (Fig. 5A).
Subsequently, we investigated the effects of the pharmaco-
logical ATP competitive GSK-3β inhibitor CT99201 on
epithelial barrier function. Of note, addition of CT99021
alone induced barrier dysfunction (Fig. 5B), and this effect
was not counteracted by either BUD or FP (Fig. 5B).
Fig. 2 Effect of equivalent concentrations of budesonide (BUD) and fluticasone propionate (FP) on cigarette smoke extract (CSE)-induced barrier
dysfunction in 16HBE cells and PBECs. 16HBE cells and PBECs were seeded in duplicates, grown to 80−90 % confluence for 3–4 days,
serum-deprived (16HBE) or placed on basal medium with transferrin and insulin (PBECs) overnight, pre-treated with or without 16 nM
BUD or 10 nM FP for 2 hours and exposed to vehicle (control) or 5 % (PBECs) or 7.5 % (16HBE cells) CSE. a Electrical resistance in
16HBE cells was measured at 400 Hz using ECIS. Resistance levels were normalized to the levels just prior to the addition of CSE or
vehicle. In the upper panel, p < 0.01 for control versus CSE, p < 0.01 for CSE versus CSE + BUD and p < 0.05 for CSE + BUD versus CSE + FP,
as analyzed by repeated measures ANOVA. The area-under-the-curve (AUC) was calculated, starting from the time-point of 12 hours after
CSE addition, and depicted shown in the lower panel. Mean ± SEM (n = 6) levels are shown. * = p< 0.05 and ** = p < 0.01 between the indicated groups
(repeated measures ANOVA with Bonferroni’s post-hoc test). b Capacitance in 16HBE cells was measured at 40 kHz during 24 hours using ECIS and mean
levels ± SEM are shown (n = 6). c, d Resistance in PBECs was measured at 400 Hz. Resistance levels (Mean ± SEM, n = 5) were normalized to the values
prior to addition of CSE. The AUC was calculated and levels were analyzed by repeated measures ANOVA (with Bonferroni’s post-hoc test). * = p < 0.05,
** = p< 0.01 and *** = p < 0.001 between the indicated groups
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Furthermore, neither BUD nor FP significantly reduced
CSE (7.5 %)-induced barrier dysfunction in the presence
of CT99021 (Fig. 5C). This indicates that BUD no longer
protects against CSE-induced barrier dysfunction when
GSK-3β activity is blocked. Together, our results indicate
that BUD exerts stronger protective effects than FP on
CSE-induced barrier dysfunction in 16HBE cells and
PBECs, and that the effect of BUD likely involves the at-
tenuation of EGFR-dependent inactivation of GSK-3β as
demonstrated in 16HBE cells.
Effects of BUD and FP on poly-(I:C)-induced barrier
dysfunction of 16HBE cells in the presence and absence
of CSE
Additionally, we studied whether BUD and FP also
differently affect epithelial barrier function upon a dif-
ferent insult, i.e. viral mimetic poly-(I:C). Similar to
the effects of CSE and EGF, poly-(I:C) (12.5 μg/ml)
markedly reduced epithelial resistance (400 Hz,
Fig. 6A), the effect being most pronounced between
12–48 hours. In contrast to the differential effects of
BUD and FP on CSE-induced barrier dysfunction,
both BUD (16 nM) and FP (10 nM) significantly
counteracted poly-(I:C)-induced epithelial barrier dys-
function. As for the involved mechanism, Rezaee
et al. previously reported that poly-(I:C) disrupts
epithelial integrity at 24 hours by a protein kinase D
(PKD)-dependent mechanism [29] . However, we ob-
served that the early poly-(I:C)-induced disruption of
16HBE cell-cell interactions, as measured by low-
frequency resistance, could not be blocked by 5 μM
PKD inhibitor Gö6976 (data now shown).
Next, we investigated the effect of BUD and FP upon
barrier dysfunction induced by the combination of poly-
(I:C) and 7.5 % CSE (Fig. 6B). Of note, treatment with
BUD protected significantly against the defect in barrier
function induced by the combination of CSE and poly-
(I:C), while the smaller effect of FP was not statistically
significant (Fig. 6B) and the difference between the effect
of BUD and FP was significant. Thus, whereas BUD and
FP are equally effective in the protection against poly-
(I:C)-induced barrier dysfunction, only BUD efficiently
Fig. 3 Effect of cigarette smoke extract (CSE) and equivalent concentrations of budesonide (BUD) and fluticasone propionate (FP) on cell-cell
contact proteins in 16HBE cells. 16HBE cells were seeded in duplicates, grown to confluence, serum-deprived overnight, pre-treated with or without
16 nM BUD or 10 nM FP for 2 hours and exposed to vehicle (control) or 7.5 % CSE (a) E-cadherin and ZO-1 protein was detected by western blotting
after 24 hours. Actin was used as loading control. Densitometry was performed, protein expression was related to the actin levels and normalized
values (Mean ± SEM, n = 3) are shown. b mRNA was isolated after 6 hours. E-cadherin expression was related to the expression of the housekeeping
genes β2μG and PPIA and levels (Mean ± SEM, n = 4) are expressed as fold change compared to the control (2-ΔΔCt). c Immunofluorescent staining for
ZO-1 was performed after 24 hours. A representative of 3 independent experiments is shown
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counteracts the barrier dysfunction induced by CSE
alone or in concerted action with poly-(I:C).
To enhance the relevance of our findings, we aimed to
study the effects of BUD and FP on live virus-induced
barrier dysfunction in ALI-differentiated mucociliary
epithelium, reflecting the epithelial layer in vivo more
closely. We exposed the cells to RV16, which was previ-
ously shown to reduce barrier function in 16HBE cells
[13]. However, we were unable to observe effects on epi-
thelial barrier function upon exposure to RV16. Epithe-
lial resistance levels dropped considerably as soon as
vehicle was added to the apical site of the ALI culture
and the cells were no longer air-exposed, and then an
additional effect of RV16 exposure was not observed
(data not shown). Furthermore, RV16 exposure for
24 hours did not alter mRNA expression of E-cadherin,
nor did pre-treatment with BUD. In contrast, pre-
treatment with FP significantly reduced E-cadherin in
RV16-exposed epithelium, with a significant difference
between BUD and FP (Fig. 7A). Treatment with FP, but
not BUD, may thus lead to deterioration of epithelial
barrier dysfunction upon viral infection.
Finally, we assessed the effect of live bacteria on
barrier function, and studied whether exposure to poly-
(I:C) enhances bacterial adhesion/internalization and/or
transmigration across the cell interior. The infection of
16HBE cells with S. pneumoniae caused a strong de-
crease in transepithelial resistance, on which BUD, but
not FP, exerted a modest but significant protective effect
(Fig. 7B). Within the time frame of our experiment, the
concomitant exposure to the bacteria and poly-(I:C) did
not affect epithelial transmigration of bacteria (data not
shown). However, poly-(I:C) strongly increased CFUs in
the cell lysates, indicating that poly-(I:C) promotes
Fig. 4 Effect of equivalent concentrations of budesonide (BUD) and
fluticasone propionate (FP) on EGF-induced barrier dysfunction and
EGF activity in 16HBE cells. a 16HBE cells were seeded in duplicates,
grown to confluence, serum-deprived overnight, pre-treated with or
without 16 nM BUD or 10 nM FP for 2 hours and exposed to vehicle
(control) or EGF. Resistance was measured at 400 Hz using ECIS.
Resistance levels were normalized to the levels prior to the addition
of 7.5 % CSE or vehicle. Mean ± SEM levels (n = 3) are shown. In the
upper panel, p < 0.01 for control versus EGF, p < 0.01 for EGF versus
EGF + BUD and p < 0.01 for EGF + BUD versus EGF + FP, as analyzed by
repeated measures ANOVA. The area-under-the-curve (AUC) was
calculated and mean ± SEM levels (n = 3) are shown. * = p < 0.05 and
** = p < 0.01 between the indicated groups (repeated measures
ANOVA with Bonferroni’s post-hoc test). b 16HBE cells were grown to
confluence, serum-deprived overnight, pre-treated with or without 16
nM BUD or 10 nM FP for 2 hours and exposed to vehicle (control) or
EGF for 60 min. Phosphorylated EGF receptor (p-EGFR) or total EGFR
was detected by western blotting. GAPDH was used as loading
control. Densitometry was performed, protein expression was
related to the actin levels and normalized values (Mean ± SEM,
n = 6) are shown. * = p < 0.05 between the indicated groups as
determined by the Student’s t-test
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Fig. 5 Effect of equivalent concentrations of budesonide (BUD) and fluticasone propionate (FP) on GSK-3β phosphorylation and epithelial barrier
dysfunction upon pharmacological inhibition of GSK-3β. a 16HBE cells were seeded in duplicates, grown to confluence, serum-deprived overnight,
pre-treated with or without 16 nM BUD and 10 nM FP for 60 min and exposed to vehicle (control) or EGF for 60 min. Phosphorylated
GSK-3β (p-GSK-3β) or total GSK-3β was detected by western blotting. GAPDH was used as loading control. Densitometry was performed, protein
expression was related to the actin levels and normalized values (Mean ± SEM, n = 6) are shown. * = p < 0.05 between the indicated groups. b, c)
16HBE cells were grown to confluence, serum-deprived overnight, pre-treated with or without 16 nM BUD and 10 nM FP for 2 hours and exposed to
vehicle (control), GSK-3β inhibitor CT99021 (b) or the combination of 7.5 % CSE and CT99021 c. Electrical resistance was measured at 400 Hz using ECIS.
Resistance levels were normalized to the levels prior to the addition of CSE and/or CT99021. Mean ± SEM levels (n = 3−4) are shown. In the upper
panels (b and c), p < 0.01 for CT99021 and CT99201 + CSE versus control, as analyzed by repeated measures ANOVA. The area-under-the-curve (AUC)
was calculated and mean ± SEM levels (n = 3−4) are shown. * = p < 0.05 between the indicated groups (repeated measures ANOVA with Bonferroni’s
post-hoc test)
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bacterial adhesion and/or internalization (Fig. 7C). This
effect was prevented by BUD, which may thus act to de-
crease susceptibility to secondary bacterial infection; in
contrast FP had no effect (Fig. 7C).
Discussion
We hypothesized that BUD is more efficacious than FP
in the protection of airway epithelial barrier function
upon cigarette smoking or viral infection, potentially
contributing to the ICS’ differential risk associated with
pneumonia in COPD. Our results show that BUD pro-
tects more effectively than FP against CSE-induced
bronchial epithelial barrier dysfunction, either alone or
in combination with viral mimetic poly-(I:C), while BUD
and FP equally effectively protect against poly-(I:C)-in-
duced barrier dysfunction. Furthermore, both BUD and
FP strongly suppress CSE and/or poly-(I:C)-induced
pro-inflammatory cytokine production in bronchial epi-
thelial cells lines and PBECs of smokers without signifi-
cant differences between the drugs. Our findings may
have important implications, since they help to explain
the clinical observations that treatment with BUD is not,
or seldom associated with an increased risk to develop
pneumonia in patient with COPD, in contrast to FP.
The present study suggests that this is unlikely a conse-
quence of increased immunosuppression by FP. Instead,
treatment of COPD patients with BUD could provide
better protective effects against cigarette smoke-induced
epithelial damage than FP, reinforcing the epithelial bar-
rier. This may limit the access of pathogens upon
cigarette smoking in the presence or absence of a viral
infection in vivo. Indeed, we observed that BUD pro-
tected against the poly-(I:C)-induced increase in bacter-
ial adhesion and/or internalization. This effect may be
mediated by the reinforcement of the epithelial barrier,
as epithelial junctions functionally segregate the basolat-
eral from the apical site. RV-induced disruption of epi-
thelial barrier function may thus increase the exposure
of cell surface receptors for bacterial binding [30].
Whether loss of epithelial polarity indeed acts to en-
hance binding of S. pneumoniae to surface receptors will
require further investigation. Our findings on the re-
duced expression of E-cadherin mRNA in RV16-exposed
differentiated epithelium upon FP treatment suggest that
the treatment with FP, but not BUD, may aggravate RV-
induced barrier disruption in vivo, and thus increase the
risk of a secondary bacterial infection.
Our data indicate that the differential effects of BUD
and FP on epithelial barrier function are due to differ-
ences in their effect on specific pathways involved in
barrier dysfunction upon CSE exposure. While BUD at-
tenuated the EGF-induced phosphorylation of EGFR and
its downstream target GSK-3β, FP was not able to do so.
This inhibitory effect of BUD on EGFR signaling could
Fig. 6 Effect of equivalent concentrations of budesonide (BUD) and
fluticasone propionate (FP) on cigarette smoke extract (CSE) and/or
poly-(I:C)-induced barrier dysfunction in 16HBE cells. 16HBE cells were
seeded in duplicates, grown to confluence, serum-deprived overnight,
pre-treated with or without 16 nM BUD or 10 nM FP for 2 hours and
exposed to vehicle (control), poly-(I:C) (a) or 7.5 % CSE plus poly-(I:C)
(b). Resistance was measured at 400 Hz using ECIS. Resistance levels
were normalized to the levels prior to the addition of poly-(I:C) and
mean ± SEM levels (n = 3−4) are shown. In the upper panels, p < 0.01
for control versus poly-(I:C), p < 0.05 for poly-(I:C) versus poly-(I:C) +
BUD and poly-(I:C) + FP (a), p = 0.05 for control versus CSE + poly-(I:C),
p < 0.05 for CSE + poly-(I:C) versus CSE + poly-(I:C) + BUD and p < 0.001
for CSE + poly-(I:C) + BUD versus CSE + poly-(I:C) + FP (b), as analyzed
by repeated measures ANOVA. The area-under-the-curve (AUC) was
calculated and mean ± SEM levels (n = 3−4) are shown. * = p < 0.05
and ** = p < 0.01 between the indicated groups (repeated measures
ANOVA with Bonferroni’s post-hoc test)
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be involved in the protective effect of BUD on CSE-
induced barrier dysfunction, since we have previously re-
ported that CSE-induced EGFR phosphorylation results
in epithelial barrier dysfunction by delocalization of ZO-
1 from tight junctions [12]. CSE has also been described
to inhibit GSK-3β activity by its phosphorylation at Ser9
in lung epithelial cells [31]. To our knowledge, we are
the first to demonstrate that pharmacological inhibition
of GSK-3β results in epithelial barrier dysfunction, sug-
gesting that the attenuation of EGFR-dependent GSK-3β
phosphorylation by BUD is involved in the protective ef-
fect of BUD on epithelial barrier function. We observed
that BUD was not able to restore epithelial barrier
dysfunction upon pharmacological inhibition of GSK-3β,
indicating that GSK-3β activation is indispensable for
the responsiveness of the epithelial barrier to BUD,
in line with previous findings in lymphoma cells [32].
GSK-3β can induce degradation of transcriptional re-
pressor Slug/Snail2 [33], leading to upregulation of
E-cadherin, ZO-1, claudins and occludin expression
[34]. Since E-cadherin mRNA expression was not af-
fected by CSE and corticosteroids in our setting,
transcriptional regulation of junctional proteins does
not likely contribute to the observed effects on
epithelial barrier function. Alternatively, Snail can in-
duce disruption of tight junction complexes at the
Fig. 7 Effects of equivalent concentrations of budesonide (BUD) and fluticasone propionate (FP) pre-treatment on rhinovirus (RV16)-exposed
primary mucociliary epithelium and Streptococcus pneumonia-exposed 16HBE cells. a PBECs were seeded in duplicates in the apical compartment
of a transwell system, grown to confluence, differentiated at air-liquid interface for 4 weeks, placed in hormonally-deprived medium overnight,
pre-treated with or without 16 nM BUD or 10 nM FP for 2 hours and infected with 50 μl RV16 with an multiplicity of infection of 1 for 24 hours
at 37 °C. E-cadherin expression was related to the expression of the housekeeping genes β2μG and PPIA and levels (Mean ± SEM, n = 10) are
expressed as fold change compared to the control (2-ΔΔCt). b 16HBE cells were seeded in duplicates in the apical compartment of a transwell
system, grown to confluence, serum-deprived overnight, pre-treated with or without 16 nM BUD or 10 nM FP for 2 hours and exposed to
Streptococcus pneumoniae in the presence and absence of poly-(I:C) for 24 hours. Transepithelial resistance (TER) levels (Ω, mean ± SEM, n = 7)
(c) Colony forming units (CFUs) in 16HBE cell lysates. Invasion in the presence of poly-(I:C) was set at 1 and normalized values are shown (mean
± SEM, n = 7). * = p < 0.05 and *** = p < 0.001 between the indicated groups as determined by the Wilcoxon-signed rank test
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posttranslational level, by causing alternative splicing
of ZO-1, resulting in higher expression of the ZO-1
isoform that is involved in junctional plasticity [34].
Future studies will have to determine whether EGFR-
dependent GSK-3β inactivation and subsequent deg-
radation of Snail are involved in CSE-mediated
disruption of epithelial junctions. In addition to its
effects on barrier function, GSK-3β has been implicated in
inflammatory responses to bacterial infection [35]. Fur-
thermore, side-stream cigarette smoke-induced inactiva-
tion of GSK-3β was shown to increase the susceptibility to
adenovirus by the upregulation of its receptor in airway
epithelial cells [36], with additional implications for the
susceptibility to microbial infection.
It is not fully clear why BUD is more efficient than FP
in suppressing the CSE-induced EGFR/GSK-3β pathway,
while these ICS are equally effective in suppressing pro-
inflammatory cytokine production and providing protec-
tion against barrier dysfunction by viral mimicry. It
could be speculated that different pathways are involved
in these specific processes, although the pathways in-
volved in poly-(I:C)-induced barrier dysfunction need
further investigation. With respect to their physicochem-
ical properties, BUD is less lipophilic than FP and has a
higher aqueous solubility, leading to a faster dissolution
rate and a shorter retention time in the lining fluid of
the airways. By contrast, after absorption from the air-
way lumen, BUD is retained in the airway epithelium for
a longer time than FP [9, 10]. This is due to the conjuga-
tion of BUD with endogenous fatty acids, resulting in a
very lipophilic ester depot from which BUD is slowly re-
leased [9]. This prolongs anti-inflammatory effects of
BUD in the airway tissue [37] and may possibly also pro-
long effects of BUD on specific intracellular pathways.
Fatty acid esterification of BUD has also been detected
in the human lungs [38]. Further studies are required to
elucidate whether BUD and FP exert differential effects
on pathways involved in pro-inflammatory and anti-
microbial responses to viral infection. Additionally, re-
cent findings in human bronchial epithelial cells show
that a given glucocorticosteroid induces a unique gene
expression “fingerprint” [39], and this may explain some
of the differences observed between BUD and FP in the
present study.
Conclusions
Together, our data show that BUD is more efficient
in the protection against cigarette smoke-induced epi-
thelial barrier dysfunction than FP, and suggest that
this is due to more efficient suppression of EGFR/
GSK-3β signaling. We anticipate that this may have
important implications for the reinforcement of air-
way epithelial barrier function upon cigarette smoking
in vivo, where treatment with BUD could provide
better protective effects than FP, limiting the access
of pathogens.
Abbreviations
BUD: budesonide; BEGM: bronchial epithelium growth medium; COPD: Chronic
Obstructive Pulmonary Disease; ECIS: Electric Cell-surface Impedance Sensing;
EGFR: epidermal growth factor receptor; FEV: forced expiratory volume;
GSK-3: glycogen synthase kinase-3; ICS: inhaled corticosteroids; FP: fluticasone
propionate; PBECs: primary bronchial epithelial cells; ZO-1: zona occludens.
Competing interests
None of the authors has anything to disclose.
Authors’ contributions
IH contributed to the design of the work, data analysis and interpretation,
drafting and revising of the manuscript. MJ was involved in the acquisition,
analysis and interpretation of the data and critical review of the manuscript.
MdV helped to set up the experiments with virus. NtH and ET were involved
in the inclusion of subjects and critical review of the manuscript. AvO
contributed to the design of the work and critical review of the
manuscript. DP contributed to the design of the work, drafting and
critical revision of the manuscript. MvdB contributed to the design of
the work, drafting and critical revision of the manuscript. All authors
have critically read and approved the manuscript.
Acknowledgements
This study was funded by research grant SEML-89KDE8 by AstraZeneca.
Author details
1Department of Pathology & Medical Biology, Experimental Pulmonology
and Inflammation Research, University of Groningen, University Medical
Center Groningen,, Hanzeplein 1, NL-9713 GZ, Groningen, The Netherlands.
2Department of Pulmonology, University of Groningen, University Medical
Center Groningen, Groningen, The Netherlands. 3University of Groningen,
University Medical Center Groningen, GRIAC Research Institute, Groningen,
The Netherlands.
Received: 6 November 2015 Accepted: 23 December 2015
References
1. Telenga ED, Kerstjens HA, Postma DS, Ten Hacken NH, van den Berge M.
Inhaled corticosteroids in chronic obstructive pulmonary disease: a review.
Expert Opin Pharmacother. 2010;11(3):405–21.
2. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.
TORCH investigators: Salmeterol and fluticasone propionate and survival in
chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.
3. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk
A, Thiadens HA, et al. Groningen Leiden Universities Corticosteroids in
Obstructive Lung Disease Study Group: Effect of fluticasone with and
without salmeterol on pulmonary outcomes in chronic obstructive
pulmonary disease: a randomized trial. Ann Intern Med. 2009;151(8):517–27.
4. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and
the risk of pneumonia in chronic obstructive pulmonary disease: a
meta-analysis. Arch Intern Med. 2009;169(3):219–29.
5. Sin DD, Tashkin D, Zhang X, Radner F, Sjobring U, Thoren A, et al.
Budesonide and the risk of pneumonia: a meta-analysis of individual patient
data. Lancet. 2009;374(9691):712–9.
6. Janson C, Larsson K, Lisspers KH, Stallberg B, Stratelis G, Goike H, et al.
Pneumonia and pneumonia related mortality in patients with COPD treated
with fixed combinations of inhaled corticosteroid and long acting beta2
agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306.
7. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and
the risk of serious pneumonia. Thorax. 2013;68(11):1029–36.
8. Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in
COPD and the risk reduction of pneumonia. Chest. 2015;148(5):1177–83.
9. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlback M, Tunek A, Brattsand R.
Reversible fatty acid conjugation of budesonide. Novel mechanism for
prolonged retention of topically applied steroid in airway tissue. Drug
Metab Dispos. 1998;26(7):623–30.
Heijink et al. Respiratory Research  (2016) 17:2 Page 12 of 13
10. Borchard G, Cassara ML, Roemele PE, Florea BI, Junginger HE. Transport and
local metabolism of budesonide and fluticasone propionate in a human
bronchial epithelial cell line (Calu-3). J Pharm Sci. 2002;91(6):1561–7.
11. Hogg JC. Bronchial mucosal permeability and its relationship to airways
hyperreactivity. Eur J Respir Dis Suppl. 1982;122:17–22.
12. Heijink IH, Brandenburg SM, Postma DS, van Oosterhout AJ. Cigarette
smoke impairs airway epithelial barrier function and cell-cell contact
recovery. Eur Respir J. 2012;39(2):419–28.
13. Sajjan U, Wang Q, Zhao Y, Gruenert DC, Hershenson MB. Rhinovirus Disrupts
the Barrier Function of Polarized Airway Epithelial Cells. Am J Respir Crit
Care Med. 2008;178(12):1271–81.
14. Kimura K, Teranishi S, Kawamoto K, Nishida T. Protective effect of
dexamethasone against hypoxia-induced disruption of barrier function in
human corneal epithelial cells. Exp Eye Res. 2011;92(5):388–93.
15. Wadsworth SJ, Nijmeh HS, Hall IP. Glucocorticoids increase repair potential
in a novel human airway epithelial wounding model. J Clin Immunol. 2006;
26(4):376–87.
16. Ma C, Martins-Green M. Second-hand cigarette smoke inhibits wound
healing of the cornea by stimulating inflammation that delays corneal
reepithelialization. Wound Repair Regen. 2009;17(3):387–96.
17. Hewson CA, Jardine A, Edwards MR, Laza-Stanca V, Johnston SL. Toll-like
receptor 3 is induced by and mediates antiviral activity against rhinovirus
infection of human bronchial epithelial cells. J Virol. 2005;79(19):12273–9.
18. Teng F, Slavik V, Duffy KE, San Mateo L, Goldschmidt R. Toll-like receptor 3 is
involved in airway epithelial cell response to nontypeable Haemophilus
influenzae. Cell Immunol. 2010;260(2):98–104.
19. Heijink IH, Kies PM, Kauffman HF, Postma DS, van Oosterhout AJ, Vellenga E.
Down-regulation of E-cadherin in human bronchial epithelial cells leads to
epidermal growth factor receptor-dependent Th2 cell-promoting activity.
J Immunol. 2007;178(12):7678–85.
20. Heijink IH, Postma DS, Noordhoek JA, Broekema M, Kapus A. House dust
mite-promoted epithelial-to-mesenchymal transition in human bronchial
epithelium. Am J Respir Cell Mol Biol. 2010;42(1):69–79.
21. Gradstedt H, Iovino F, Bijlsma JJ. Streptococcus pneumoniae invades
endothelial host cells via multiple pathways and is killed in a lysosome
dependent manner. PLoS One. 2013;8(6):e65626.
22. Slebos DJ, Ryter SW, Van Der TM, Liu F, Guo F, Baty CJ, et al. Mitochondrial
localization and function of heme oxygenase-1 in cigarette smoke-induced
cell death. Am J Respir Cell Mol Biol. 2007;36(4):409–17.
23. Heijink IH, Brandenburg SM, Noordhoek JA, Postma DS, Slebos DJ, van
Oosterhout AJ. Characterisation of cell adhesion in airway epithelial cell
types using electric cell-substrate impedance sensing. Eur Respir J. 2010;
35(1399–3003; 0903–1936; 4):894–903.
24. Wegener J, Keese CR, Giaever I. Electric cell-substrate impedance sensing
(ECIS) as a noninvasive means to monitor the kinetics of cell spreading to
artificial surfaces. Exp Cell Res. 2000;259(1):158–66.
25. Heijink IH, Vellenga E, Oostendorp J, de Monchy JG, Postma DS, Kauffman HF.
Exposure to TARC alters beta2-adrenergic receptor signaling in human peripheral
blood T lymphocytes. Am J Physiol Lung Cell Mol Physiol. 2005;289(1):L53–9.
26. Heijink IH, Marcel KP, van Oosterhout AJ, Postma DS, Kauffman HF, Vellenga E.
Der p, IL-4, and TGF-beta cooperatively induce EGFR-dependent TARC
expression in airway epithelium. Am J Respir Cell Mol Biol. 2007;36(3):351–9.
27. Yun SI, Yoon HY, Jeong SY, Chung YS. Glucocorticoid induces apoptosis of
osteoblast cells through the activation of glycogen synthase kinase 3beta.
J Bone Miner Metab. 2009;27(2):140–8.
28. Smith E, Coetzee GA, Frenkel B. Glucocorticoids inhibit cell cycle progression in
differentiating osteoblasts via glycogen synthase kinase-3beta. J Biol Chem.
2002;277(20):18191–7.
29. Rezaee F, Meednu N, Emo JA, Saatian B, Chapman TJ, Naydenov NG, et al.
Polyinosinic:polycytidylic acid induces protein kinase D-dependent
disassembly of apical junctions and barrier dysfunction in airway epithelial
cells. J Allergy Clin Immunol. 2011;128(6):1216–24. e11.
30. Dragsten PR, Handler JS, Blumenthal R. Asymmetry in epithelial cells: is the
tight junction a barrier to lateral diffusion in the plasma membrane? Prog
Clin Biol Res. 1982;91:525–36.
31. Tian D, Zhu M, Li J, Ma Y, Wu R. Cigarette smoke extract induces activation
of beta-catenin/TCF signaling through inhibiting GSK3beta in human
alveolar epithelial cell line. Toxicol Lett. 2009;187(1):58–62.
32. Spokoini R, Kfir-Erenfeld S, Yefenof E, Sionov RV. Glycogen synthase kinase-3
plays a central role in mediating glucocorticoid-induced apoptosis. Mol
Endocrinol. 2010;24(6):1136–50.
33. Kim JY, Kim YM, Yang CH, Cho SK, Lee JW, Cho M. Functional regulation of
Slug/Snail2 is dependent on GSK-3beta-mediated phosphorylation. FEBS J.
2012;279(16):2929–39.
34. Ohkubo T, Ozawa M. The transcription factor Snail downregulates the tight
junction components independently of E-cadherin downregulation. J Cell
Sci. 2004;117(Pt 9):1675–85.
35. Cortes-Vieyra R, Bravo-Patino A, Valdez-Alarcon JJ, Juarez MC, Finlay BB,
Baizabal-Aguirre VM. Role of glycogen synthase kinase-3 beta in the
inflammatory response caused by bacterial pathogens. J Inflamm (Lond).
2012;9(1):23. -9255-9-23.
36. Sharma P, Kolawole AO, Core SB, Kajon AE, Excoffon KJ. Sidestream smoke
exposure increases the susceptibility of airway epithelia to adenoviral
infection. PLoS One. 2012;7(11):e49930.
37. Miller-Larsson A, Jansson P, Runstrom A, Brattsand R. Prolonged airway
activity and improved selectivity of budesonide possibly due to
esterification. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1455–61.
38. van den Brink KI, Boorsma M. Staal-van den Brekel, AJ, Edsbacker, S,
Wouters, EF, Thorsson, L: Evidence of the in vivo esterification of
budesonide in human airways. Br J Clin Pharmacol. 2008;66(1):27–35.
39. Joshi T, Johnson M, Newton R, Giembycz M. An analysis of glucocorticoid
receptor-mediated gene expression in BEAS-2B human airway epithelial
cells identifies distinct, ligand-directed, transcription profiles with
implications for asthma therapeutics. Br J Pharmacol. 2015;172(5):1360–78.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Heijink et al. Respiratory Research  (2016) 17:2 Page 13 of 13
